Novel approaches for the discovery of anticancer agents. Abstracts from a symposium. Freiburg, Germany. June 18-21, 2003.

H. Fiebig
Onkologie
Abstract:sDokumentation und Evaluation der Weiterbildung Onkologie 2003;26:381–399 © 2003 S. Karger GmbH, Freiburg Accessible online at: www.karger.com/onk Fax +49 761 4 52 07 14 E-mail Information@Karger.de www.karger.com so far unknown genes. At present, results of a series of SAGE libraries from several diseased and healthy tissues are online available at the NCI. Due to the digital nature of such results a comparison of new libraries to already existing ones represents a promising approach for identifying novel – previously unknown – disease-related genes. Furthermore, with the advent of the microarray technology it became possible to perform global, parallel gene expression analysis (e.g. diseased vs. healthy tissue) in a high throughput manner. This technology will greatly impact our understanding of the pathogenesis of malignant diseases. Several hallmark studies have already demonstrated, that gene expression patterns derived from microarray based approaches allow a better responder/non-responder prediction towards specific drug treatments. In addition, these new prognostic gene expression parameters have been shown to outperform current existing clinical parameters in predicting disease outcome for certain tumor types (2–4). At memorec both expression profiling platforms – SAGETM (licensed from GMO) and PIQORTM microarray analysis – have been established several years ago. Currently, in one of our gene expression profiling programs, we are combining these platforms in order to identify drug target candidate genes and diagnostic/prognostic marker genes linked to skin diseases. Together with a clinical network of experts encompassing the dermatological departments of the universities of Aachen (Prof. Dr. Merk), Bonn (Prof. Dr. Dr. Bieber), and Cologne (Prof. Dr. Krieg) we are performing gene expression analysis of about 800 patient biopsies afflicted with inflammatory skin diseases (atopic-, contact dermatitis, and psoriasis) and skin cancer (malignant melanoma, basaliom, and spinocellular carcinoma). All genes identified in the SAGETM based genome wide screen specific for normal and diseased skin are cloned, sequenced and used to complete an already existing PIQORTM Skin array comprising about 1300 genes. These arrays are currently used to generate expression profiles of abovementioned patient biopsies. The profiles are stored in a data base (SkinSAYS DB) and are analysed by state of the art bioinformatics to identify the most relevant genes/gene patterns for the respective disease. Critical issues and requirements for setting up the SkinSAYS data base (such as SOPs for experimental design, quality control management of biopsies, amount of starting material for analysis etc.) as well as first results will be discussed in the talk.
What problem does this paper attempt to address?